Skip to main navigation menu Skip to main content Skip to site footer
rd-24

Articles

Fight against Huachicol

Immune biotechnological use of monoclonal antibodies for cancer therapy

DOI
https://doi.org/10.32399/icuap.rdic.2448-5829.2019.13.390
Submitted
March 1, 2021
Published
January 15, 2019

Abstract

Extensive research in cancer has led to the development of more specific therapies against tumor cells. Monoclonal antibodies are highly specific recombinant proteins, produced by the fusion of B lymphocytes and myelomas. They can recognize and bind to antigens, so they have been applied to the areas of biology, biotechnology, immunotherapy, and health sciences. Monoclonal antibodies have been used to develop cancer therapies because they can inhibit signals for tumor growth and induce responses towards the destruction of tumor cells. This application is known as immunobiotechnology. The potential application of monoclonal antibodies has produced three generations of these proteins, which have continuously evolved to improve their effectiveness, making this type of technology one of the greatest areas of developmentin pharmacy and biotechnology. Recently, the development of monoclonal antibodies has been focused on the most common types of cancer in people.

References

  1. Berman, D., Korman, A., Peck, R., Feltquate, D., Lonberg, N. y Canetta, R. (2015). The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience. Pharmacology and Therapeutics, 148, 132-153. https://doi.org/10.1016/j.pharmthera.2014.11.017
  2. Bethune, M. T. y Joglekar, A. V. (2017). Personalized T cell-mediated cancer immunotherapy: progress and challenges. Current Opinion in Biotechnology, 48, 142-152. https://doi.org/10.1016/j.copbio.2017.03.024
  3. Couzin-Frankel, J. (2013). Cancer Immunotherapy. Science, 342(6165), 1432-1433. https://doi.org/10.1126/science.342.6165.1432
  4. Dávila, A. L. (2011). El espacio de la biotecnología en el control del cáncer: oportunidades y desafíos en Cuba The place of biotechnology in the control of cancer: opportunities and challenges in Cuba, 37, 661-674.
  5. Eisenbeis, A. M. y Grau, S. J. (2012). Monoclonal antibodies and Fc fragments for treating solid tumors. Biologics: Targets and Therapy, 6, 13-20. https://doi.org/10.2147/BTT.S19955
  6. Et, A. (2006). Anticuerpos monoclonales: desarrollo físico y perspectivas terapéuticas Monoclonal antibodies: physical development and therapeutic perspectives, 186-197.
  7. Geskin, L. J. (2015). Monoclonal Antibodies. Cutaneous lymphoma. Antibody therapy. Antibody conjugates. Clinical trials. Dermatologic Clinics, 33(4), 777-786. https://doi.org/10.1016/j.det.2015.05.015
  8. Guerra, R. S. T. y Guerra, P. T. (2008). Artículo de revisión. Impacto de la biotecnología en la inmunología, 10(39), 92-101.
  9. Henricks, L. M., Schellens, J. H. M., Huitema, A. D. R. y Beijnen, J. H. (2015). The use of combinations of monoclonal antibodies in clinical oncology. Cancer Treatment Reviews, 41(10), 859-867. https://doi.org/10.1016/j.ctrv.2015.10.008
  10. Immunology, M. O. J. (2016). Advances in Monoclonal Antibodies Production and Cancer Therapy, 3(4), 4-8. https://doi.org/10.15406/moji.2016.03.00099
  11. Li, F., Vijayasankaran, N., Shen, A. Y., Kiss, R., Li, F., Vijayasankaran, N., ... Amanullah, A. (2017). Cell culture processes for monoclonal antibody production Cell culture processes for monoclonal antibody production, 862(Noviembre). https://doi.org/10.4161/mabs.2.5.12720
  12. Liu, J. K. H. (2014). The history of monoclonal antibody development—Progress, remaining challenges and future innovations. Annals of Medicine and Surgery, 3(4), 113-116. https://doi.org/10.1016/j.amsu.2014.09.001
  13. Merino, A. G. (2011). Anticuerpos monoclonales. Aspectos basicos, 26(5). https://doi.org/10.1016/j.nrl.2010.10.005
  14. Montes-Vera, M. R., Garrido-Acosta, O., Anguiano-Robledo, L., Sánchez-Navarrete, J. y Pérez-Cruz, E. (2013). Aspectos farmacocinéticos del bevacizumab, 80(1), 73-78.
  15. Mora, N. y Rosales, C. (2009). Funciones de receptores Fc en mecanismos de defensa y regulación inmunólogica. Revista de Investigacion Clínica, 61(4), 313-326.
  16. Neves, H. y Kwok, H. F. (2015). Recent advances in the fi eld of anti-cancer immunotherapy. BBACLI, 3, 280-288. https://doi.org/10.1016/j.bbacli.2015.04.001
  17. Oldham, R. K., Dillman, R. O., Cancer, H. y Beach, N. (2017). Monoclonal Antibodies in Cancer Therapy: 25 Years of Progress, 26(11), 1774-1777. https://doi.org/10.1200/JC0.2007.15.7438
  18. Panda, A. K., Bose, S., Sarkar, T., Roy, D., Chakraborty, D., Chakraborty, S., ... Sa, G. (2017). Cancer-immune therapy: restoration of immune response in cancer by immune cell modulation. Nucleus (India), 60(2), 93-109. https://doi.org/10.1007/s13237-017-0194-7
  19. Ribatti, D. (2014). From the discovery of monoclonal antibodies to their therapeutic application: An historical reappraisal. Immunology Letters, 161(1), 96-99. https://doi.org/10.1016/j.imlet.2014.05.010
  20. Rodgers, K. R. y Chou, R. C. (2016). Therapeutic monoclonal antibodies and derivatives: Historical perspectives and future directions. Biotechnology Advances, 34(6), 1149-1158. https://doi.org/10.1016/j.biotechadv.2016.07.004
  21. Scott, A. M., Allison, J. P. y Wolchok, J. D. (2012). Monoclonal antibodies in cancer therapy. Cancer Immunity, 12(Mayo), 14. https://doi.org/10.1016/S1470-2045(12)70006-2
  22. Shuptrine, C. W., Surana, R. y Weiner, L. M. (2012). Monoclonal antibodies for the treatment of cancer. Seminars in Cancer Biology, 22(1), 3-13. https://doi.org/10.1016/j.semcancer.2011.12.009
  23. Teo, E. C. Yuan, Chew, Y. y Phipps, C. (2016). A review of monoclonal antibody therapies in lymphoma. Critical Reviews in Oncology/Hematology, 97(Agosto de 2015), 72-84. https://doi.org/10.1016/j.critrevonc.2015.08.014
  24. Topalian, S. L., Weiner, G. J. y Pardoll, D. M. (2011). Cancer immunotherapy comes of age. Journal of Clinical Oncology, 29(36), 4828-4836. https://doi.org/10.1200/JCO.2011.38.0899